Key result
Prostaglandin E1 infusions achieved clinical improvement at all doses, with side effects being dose-related and no serious side effects noted at 0.005 to 0.01 micrograms/kg/minute.
Why the study?
Does intravenous prostaglandin E1 safely improve clinical status in neonates with suspected duct-dependent cardiac malformations?
Population
52 sick neonates with major duct dependent cardiac defects
Design
Case_series
Follow-up
short term
Authors
Loading...
Supports low-dose PGE1 for neonatal stabilization; case report leaves open need for prospective validation.
Does intravenous prostaglandin E1 safely improve clinical status in neonates with suspected duct-dependent cardiac malformations?
Low-dose intravenous prostaglandin E1 (0.005 to 0.01 micrograms/kg/minute) is an effective and safe initial regimen for stabilizing neonates with suspected duct-dependent cardiac defects prior to transfer.
K A Hallidie-Smith (1984) studied major duct dependent cardiac defects (n=52). Prostaglandin E1 (alprostadil) was evaluated on Clinical improvement and side effects. Prostaglandin E1 infusions achieved clinical improvement at all doses, with side effects being dose-related and no serious side effects noted at 0.005 to 0.01 micrograms/kg/minute.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: